AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen

AlivaMab Discovery Services, a company providing custom human therapeutic antibody drug discovery services using the AlivaMab Mouse, a best-in-class antibody discovery platform, announced a multi-target discovery agreement with Janssen Research & Development, LLC (Janssen). Under the agreement, ADS will provide its expertise and capabilities to generate and deliver therapeutic antibody candidates to Janssen for further evaluation.

“We are pleased that Janssen, a global leader in biologic drug discovery and development, has entrusted ADS as a partner in its therapeutic antibody discovery efforts,” said “Lippy” Lippincott, PhD, Vice-President of Research. “ADS is delivering potent, picomolar-affinity human antibodies to its partners, in a greater number and a shorter timeline that beats other transgenic animal and in vitro display platforms. Our team of experts looks forward to collaborating with colleagues at Janssen in using AlivaMab Mouse to discover therapeutic antibody candidates.”